Mycoplasma pneumoniae infection and cough-variant asthma
Conditions
Interventions
Treatment group:Western medicine basic treatment + Chinese herbal medicine Lung-Clearing and Meridian-Connecting Formula
Control Group:Western medicine basic treatment +placebo
Sponsors
Tianjin Children's Hospital
Eligibility
Sex/Gender
All
Age
5 Years to 14 Years
Inclusion criteria
Inclusion criteria: The participants must meet the following criteria simultaneously: Meet the following conditions simultaneously: (1) Aged 5 - 14 years old, regardless of gender; (2) Meet the diagnostic criteria for Mycoplasma pneumoniae (MP) infection in children (symptoms of acute respiratory tract infection, and positive serum MP - IgM or positive MP - DNA PCR test of nasopharyngeal swab); (3) Meet the diagnostic criteria for cough variant asthma (CVA) in children (persistent cough > 4 weeks, often accompanied by nocturnal or early - morning attacks, positive bronchial provocation test or effective anti - asthma treatment); (4) Cough visual analogue scale (VAS) score = 30mm; (5) Meet the diagnostic criteria for wind - heat cough or phlegm - heat cough in traditional Chinese medicine (cough, yellow phlegm, discomfort in the throat, nasal congestion, yellow or turbid nasal discharge, red tongue with thin yellow or yellow greasy coating, floating and rapid or slippery and rapid pulse); (6) The legal guardians of the children voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Meet one of the following conditions: (1) Children with acute fever; (2) Patients with chronic cough due to other known causes (such as foreign body inhalation, whooping cough, pulmonary tuberculosis, etc.); (3) Patients with primary diseases of the heart, liver, kidneys, hematopoietic system, etc., or mental diseases; Known allergy to the study drug and its ingredients; (4) Systemic use of glucocorticoids or immunosuppressants within the past 4 weeks; (5) Other conditions that the researcher deems unsuitable for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Daytime and Nighttime Cough Visual Analog Scale (VAS);Mycoplasma pneumoniae DNA(MP-DNA) conversion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary Function;Exhaled Nitric Oxide (FeNO);TCM Syndrome Score;Serum cytokines (IL-17A, IL-6, IL-10, TGF-ß);The proportion of Th17 and Treg cells in peripheral blood.; | — |
Countries
China
Contacts
Public ContactZhao Jiuling
Tianjin Children's Hospital
Outcome results
None listed